Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Solid Tumors 2Thrombocythemia, Essential 1Polycythemia Vera 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Glioblastoma 1Chromosome 17 deletion 1

Interventions

Gemcitabine 9Paclitaxel 8Carboplatin 7atezolizumab 6Sunitinib 5navitoclax 4Topotecan 4Irinotecan 4Docetaxel 4Bevacizumab 4pazopanib 3liposomal doxorubicin 3cobimetinib 3Nivolumab 3Erlotinib Hydrochloride 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2temsirolimus 2selicrelumab 2plocabulin 2envafolimab 2darinaparsin 2brigimadlin 2adavosertib 2Tablets 2Sorafenib 2Rifampin 2RG7388 2Panitumumab 2NVP-BKM120 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Solid Tumors × RG7388 × Clear all
NCT03362723 2019-06-19

A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
48 enrolled
Other solid neoplasm

Solid Tumors

NCT02828930 2017-12-18

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Hoffmann-La Roche

Phase 1 Completed
8 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡